Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma

被引:1
|
作者
Caro, Jessica [1 ]
Cairns, David [2 ]
Menzies, Tom [2 ]
Boyle, Eileen [1 ]
Pawlyn, Charlotte [3 ]
Cook, Gordon [2 ]
Kaiser, Martin [3 ]
Walker, Brian A. [4 ]
Owen, Roger [5 ]
Jackson, Graham H. [6 ]
Morgan, Gareth J. [1 ]
Heaney, Jennifer [7 ]
Drayson, Mark [7 ]
Davies, Faith E. [1 ]
机构
[1] NYU Langone Hlth, Perlmutter Canc Ctr, 168 E 34th St, New York, NY 10016 USA
[2] Univ Leeds, Leeds Inst Clin Trials Res, Leeds, W Yorkshire, England
[3] Inst Canc Res, London, England
[4] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[5] St James Univ Hosp, Leeds, W Yorkshire, England
[6] Newcastle Univ, Dept Hematol, Newcastle Upon Tyne, Tyne & Wear, England
[7] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England
来源
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷 / 04期
关键词
Immunosuppression; myeloma; infection; plasma cell disorder; monoclonal protein; RISK; THALIDOMIDE; THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE;
D O I
10.1016/j.clml.2021.10.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunoparesis is associated with poor survival in myeloma (MM). We demonstrate that the etiologic cytogenetic abnormality influences the degree and clinical impact of immunoparesis in newly diagnosed patients in a large clinical trial. As the depth of IgM immunoparesis impacts survival for hyperdiploid patients, this may be used to further risk-stratify this cytogenetic subgroup of patients for future clinical decisions. Introduction/Background: Immunoparesis, or low polyclonal immunoglobulin levels, is commonly seen in multiple myeloma (MM), and is associated with poor clinical outcomes. MM can be divided into subgroups with distinct biology and outcomes based on etiologic cytogenetic abnormalities. These include hyperdiploidy and translocations of t(11;14), t(4;14), t(14;16), and t(14;20), with the latter 3 associated with high-risk disease. We hypothesized that the different etiologic cytogenetic abnormalities drive bone marrow microenvironmental changes, resulting in different degrees of immunoparesis, and subgroup-dependent effects on clinical outcomes. Materials and Methods: We performed a retrospective review of 985 newly diagnosed patients enrolled in the Myeloma IX and XI trials. Immunoglobulin levels, survival outcomes, and infection rates were evaluated for each cytogenetic subgroup. Results: A significant proportion of patients with high-risk t(4;14), t(14;16), or t(14;20) had suppressed polyclonal immunoglobulins compared to standard-risk patients with hyperdiploidy or t(11;14). The clinical impact of immunoparesis depended on the cytogenetic subgroup, with the degree of IgM suppression effecting progression-free and overall survival only in the hyperdiploid subgroup. There was no significant difference in infection rates amongst the etiologic subgroups. Conclusion: These findings demonstrate that the etiologic cytogenetic subgroup influences the degree and clinical impact of immunoparesis. This suggests that the underlying cytogenetic abnormality affects remodeling of the bone marrow plasma cell niche, resulting in suppressed normal plasma cell function, and low immunoglobulin levels.
引用
收藏
页码:E279 / E284
页数:6
相关论文
共 50 条
  • [21] Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma
    Merz, Maximilian
    Jauch, Anna
    Hielscher, Thomas
    Bochtler, Tilmann
    Schoenland, Stefan Olaf
    Seckinger, Anja
    Hose, Dirk
    Bertsch, Uta
    Neben, Kai
    Raab, Marc Steffen
    Hillengass, Jens
    Salwender, Hans
    Blau, Igor Wolfgang
    Lindemann, Hans-Walter
    Schmidt-Wolf, Ingo G. H.
    Scheid, Christof
    Haenel, Mathias
    Weisel, Katja C.
    Goldschmidt, Hartmut
    BLOOD ADVANCES, 2018, 2 (01) : 1 - 9
  • [22] Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival
    Muchtar, E.
    Dispenzieri, A.
    Kumar, S. K.
    Buadi, F. K.
    Lacy, M. Q.
    Zeldenrust, S.
    Hayman, S. R.
    Leung, N.
    Kourelis, T. V.
    Gonsalves, W.
    Chakraborty, R.
    Russell, S.
    Dingli, D.
    Lust, J. A.
    Lin, Y.
    Kapoor, P.
    Go, R.
    Kyle, R. A.
    Rajkumar, S. V.
    Gertz, M. A.
    LEUKEMIA, 2017, 31 (01) : 92 - 99
  • [23] Cytogenetic abnormalities in multiple myeloma
    Paluszewska, M
    Dwilewicz-Trojaczek, J
    Stanczak, H
    Brycz-Witkowska, J
    Chmarzynska-Mróz, E
    Wasiutynski, A
    Wiktor-Jedrzejczak, W
    7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION, 2002, : 249 - 252
  • [24] Cytogenetic abnormalities in multiple myeloma
    Fonseca, R
    Coignet, LJA
    Dewald, GW
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (06) : 1169 - +
  • [25] Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival
    E Muchtar
    A Dispenzieri
    S K Kumar
    F K Buadi
    M Q Lacy
    S Zeldenrust
    S R Hayman
    N Leung
    T V Kourelis
    W Gonsalves
    R Chakraborty
    S Russell
    D Dingli
    J A Lust
    Y Lin
    P Kapoor
    R Go
    R A Kyle
    S V Rajkumar
    M A Gertz
    Leukemia, 2017, 31 : 92 - 99
  • [26] Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival
    Muchtar, Eli
    Dispenzieri, Angela
    Kumar, Shaji K.
    Buadi, Francis K.
    Lacy, Martha Q.
    Zeldenrust, Steven
    Hayman, Suzanne R.
    Leung, Nelson
    Kourelis, Taxiarchis V.
    Gonsalves, Wilson
    Chakraborty, Rajshekhar
    Russell, Steven
    Dingli, David
    Lust, John A.
    Lin, Yi
    Kapoor, Prashant
    Go, Ronald
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Gertz, Morie A.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2017, 24 : 40 - 41
  • [27] Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
    W I Gonsalves
    N Leung
    S V Rajkumar
    A Dispenzieri
    M Q Lacy
    S R Hayman
    F K Buadi
    D Dingli
    P Kapoor
    R S Go
    Y Lin
    S J Russell
    J A Lust
    S Zeldenrust
    R A Kyle
    M A Gertz
    S K Kumar
    Blood Cancer Journal, 2015, 5 : e296 - e296
  • [28] Improvement in Renal Function and Its Impact on Survival in Patients with Newly Diagnosed Multiple Myeloma
    Gonsalves, Wilson I.
    Leung, Nelson
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    Buadi, Francis
    Lacy, Martha Q.
    Dingli, David
    Kapoor, Prashant
    Go, Ronald S.
    Lust, John A.
    Hayman, Suzanne R.
    Lin, Yi
    Zeldenrust, Steven R.
    Kyle, Robert A.
    Gertz, Morie A.
    Kumar, Shaji
    BLOOD, 2014, 124 (21)
  • [29] Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
    Gonsalves, W. I.
    Leung, N.
    Rajkumar, S. V.
    Dispenzieri, A.
    Lacy, M. Q.
    Hayman, S. R.
    Buadi, F. K.
    Dingli, D.
    Kapoor, P.
    Go, R. S.
    Lin, Y.
    Russell, S. J.
    Lust, J. A.
    Zeldenrust, S.
    Kyle, R. A.
    Gertz, M. A.
    Kumar, S. K.
    BLOOD CANCER JOURNAL, 2015, 5 : e296 - e296
  • [30] The Reversal of Renal Impairment and its Impact on Survival in Newly Diagnosed Multiple Myeloma Patients
    Gonsalves, Wilson I.
    Leung, Nelson
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    Buadi, Francis K.
    Lacy, Martha Q.
    Dingli, David
    Kapoor, Prashant
    Lust, John A.
    Go, Ronald S.
    Hayman, Suzanne R.
    Lin, Yi
    Zeldenrust, Steven
    Kyle, Robert A.
    Gertz, Morie A.
    Kumar, Shaji K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S239 - S239